Recently, we identified the complex formed by GADD45β and the JNK kinase, MKK7, as an essential survival module dependent on constitutive NF-κB signalling and a novel therapeutic target in multiple myeloma (Fig. 1) (De Smaele et al., 2001; Papa et al., 2004; Tornatore et al., 2014; Tornatore et al., 2015; Papa et al., 2007). Here, MAP2K7 is linked to plasma cell myeloma.